Use filters to refine the search results.
Results 1-3 of 3
|26-May-2017||De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial||Clark, RE; Polydoros, F; Apperley, JF; Milojkovic, D; Pocock, C, et al|
|11-May-2017||E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.||Claudiani, S; Apperley, J; Gale, RP; Clark, R; Szydlo, R, et al|
|27-Jan-2017||RT-qPCR and RT-Digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia||Alikian, M; Whale, AS; Akiki, S; Piechocki, K; Torrado, C, et al|